Metraipolis › archive › dc_1cb84f2f01df

Subcutaneous versus intravenous trastuzumab for HER2-positive breast cancer: a global systematic review and meta-analysis with a cost-minimization analysis… — Europe PMC PMID:41573718

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41573718
DOI
10.3389/fphar.2025.1730175
License (as archived)
solo-consultazione
Archived
2026-11-07T00:38:32.777Z
SHA-256 of the archived text
918b76d8177812be759ea70814ee42b2d11cc732bd601c7875f0333667e0d316
Stable URL of this page
https://metraipolis.com/documento/dc_1cb84f2f01df

How to cite

Subcutaneous versus intravenous trastuzumab for HER2-positive breast cancer: a global systematic review and meta-analysis with a cost-minimization analysis… — Europe PMC PMID:41573718 — Europe PMC (en), https://europepmc.org/article/MED/41573718 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_1cb84f2f01df (Metraipolis archive dc_1cb84f2f01df, sha256 918b76d8177812be759ea70814ee42b2d11cc732bd601c7875f0333667e0d316)
BibTeX
@misc{dc1cb84f2f01df,
  title = {Subcutaneous versus intravenous trastuzumab for HER2-positive breast cancer: a global systematic review and meta-analysis with a cost-minimization analysis… — Europe PMC PMID:41573718},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41573718},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_1cb84f2f01df; sha256 918b76d8177812be759ea70814ee42b2d11cc732bd601c7875f0333667e0d316},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41573718. Agents can read the archived copy with the MCP tool read_document.